Author: Mika Mika Date: May 23, 2022
Nucleic acid-based therapeutics are revolutionizing the pharmaceutical landscape, as they can target the genetic bases of diseases rather than the downstream proteins, offering long-lasting or even potentially curative treatments for many intractable conditions. Effective gene delivery for therapeutic purposes remains a translational challenge. By developing better nucleic acid delivery systems and better understanding of the relationship between nanoparticle physico-chemical properties and their behaviours, nucleic acid therapeutics will facilitate innovative and selective targeting to specific tissue/cells. NanoFCM provides a platform for comprehensive LNP characterization, and can be widely applied in the workflow of nucleic acid therapeutics, including research and development, production/manufacturing, purification, and quality control processes.